Yazan Ghosheh, MD
Interventional Cardiology · Little Rock, ARNPI 1861706046
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,499 of the $9,560 with a category attached, or 88.9%. 29 manufacturers reported payments, led by Boston Scientific at 33.4% of the total. Reporting peaked in 2019 at $3,925 and has fallen 79.9% since, to $788 in 2025.
Across 311 payments — averaging $30.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Shockwave Medical, Inc$2K
- Abiomed$913
- Novartis$706
- Amgen$504
- Irhythm Technologies, Inc.$492
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,06111%
- Food & beverage$8,49989%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 70 | $3,192 |
| Shockwave Medical, Inc | 27 | $1,613 |
| Abiomed | 10 | $913 |
| Novartis | 55 | $706 |
| Amgen | 27 | $504 |
| Irhythm Technologies, Inc. | 12 | $492 |
| Boehringer Ingelheim | 22 | $376 |
| Johnson & Johnson | 14 | $244 |
| Inari Medical, Inc. | 1 | $170 |
| Biotronik Inc. | 1 | $140 |
| Sanofi-aventis U.S. LLC | 8 | $136 |
| Amarin Pharma, Inc. | 8 | $125 |
| AstraZeneca | 8 | $112 |
| Abbott | 5 | $111 |
| Medtronic | 5 | $87 |
| Merck | 5 | $85 |
| Cardiovascular Systems Inc. | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| Asahi Intecc USA, Inc. | 1 | $76 |
| Pfizer | 5 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $75 |
| Astellas Pharma US Inc | 2 | $44 |
| Gilead | 2 | $25 |
| Baxter Healthcare | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| United Therapeutics Corporation | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,560 in reported general payments places this provider in the 65th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 70 | $73,255 |
| EntrestoSacubitril/Valsartan | 63 | $55,488 |
| XareltoRivaroxaban | 57 | $36,202 |
| JardianceEmpagliflozin | 23 | $13,975 |
| BrilintaTicagrelor | 20 | $12,117 |
| Ranolazine ErRanolazine | 33 | $1,943 |
| Atorvastatin Calcium | 190 | $1,452 |
| Metoprolol Succinate | 81 | $1,250 |
| Bumetanide | 29 | $839 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 58 | $799 |
| Losartan Potassium | 63 | $597 |
| Amlodipine Besylate | 137 | $579 |
| Prasugrel Hcl | 13 | $559 |
| Cilostazol | 34 | $529 |
| Carvedilol | 78 | $493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $73,25570 claims |
| NovartisEntresto | $706 | $55,48863 claims |
| Johnson & JohnsonXarelto | $244 | $36,20257 claims |
| Boehringer IngelheimJardiance | $376 | $13,97523 claims |
| AstraZenecaBrilinta | $112 | $12,11720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Little Rock
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Stephen BroughtonLittle Rock$34K
- Mahesh Anantha NarayananLittle Rock$26K
- Aravind RaoLittle Rock$17K
- Patrick TobbiaLittle Rock$14K
- Subhi AlarefLittle Rock$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.